Accustem Sciences Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Accustem Sciences Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.76M) | Apr 14, 2026 |
| FY2025 | Dec 31, 2024 | ($1.51M) | Apr 14, 2026 |
| FY2024 | Dec 31, 2023 | ($2.05M) | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | ($3.75M) | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | ($670.6K) | Feb 15, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.76M) | Apr 14, 2026 |
| FY2025 | Dec 31, 2024 | ($1.51M) | Apr 14, 2026 |
| FY2024 | Dec 31, 2023 | ($2.05M) | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | ($3.75M) | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | ($670.6K) | Feb 15, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $281.0K | Apr 14, 2026 |
| FY2025 | Dec 31, 2024 | $138.3K | Apr 14, 2026 |
| FY2024 | Dec 31, 2023 | $139.7K | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | $266.9K | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | $73.3K | Feb 15, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($850.4K) | Apr 14, 2026 |
| FY2025 | Dec 31, 2024 | ($664.1K) | Apr 14, 2026 |
| FY2024 | Dec 31, 2023 | ($1.62M) | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | ($1.81M) | Mar 22, 2024 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2022 | $11.0K | Mar 22, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.55M | Apr 14, 2026 |
| FY2025 | Dec 31, 2024 | $50.9K | Apr 14, 2026 |
| FY2024 | Dec 31, 2023 | $133.9K | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | $939.7K | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | $1.35M | Feb 15, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.95M | Apr 14, 2026 |
| FY2025 | Dec 31, 2024 | $3.36M | Apr 14, 2026 |
| FY2024 | Dec 31, 2023 | $2.25M | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | $1.08M | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | $702.7K | Feb 15, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.40M) | Apr 14, 2026 |
| FY2025 | Dec 31, 2024 | ($3.31M) | Apr 14, 2026 |
| FY2025 | Dec 31, 2023 | ($2.11M) | Apr 14, 2026 |
| FY2024 | Dec 31, 2022 | ($139.6K) | Apr 3, 2025 |
| FY2023 | Dec 31, 2021 | $650.7K | Mar 22, 2024 |
| FY2022 | Dec 31, 2020 | $1.31M | Feb 15, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.78M) | Apr 14, 2026 |
| FY2025 | Dec 31, 2024 | ($8.03M) | Apr 14, 2026 |
| FY2024 | Dec 31, 2023 | ($6.52M) | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | ($4.47M) | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | ($724.9K) | Feb 15, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 14, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 14, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Feb 15, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 14, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 14, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 22, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 16.07M | Apr 14, 2026 |
| FY2025 | Dec 31, 2024 | 12.10M | Apr 14, 2026 |
| FY2024 | Dec 31, 2023 | 11.35M | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | 11.35M | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | 10.00M | Feb 15, 2023 |